Ethicon pushes for completion of tissue adhesive trials:
This article was originally published in Clinica
Executive Summary
Ethicon has given Protein Polymer Technologies until the end of the year to complete trials of its tissue adhesives (see Clinica No 673, p 1). If they are successful, Ethicon will continue to contribute to on-going R&D and regulatory costs. Ethicon and Johnson & Johnson Development, both Johnson & Johnson subsidiaries, have provided an additional $735,000 in R&D expenses. Ethicon has worldwide marketing rights and Johnson & Johnson Development has warrants for some of the biomaterials company's common stock.